108 related articles for article (PubMed ID: 1892368)
21. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
[TBL] [Abstract][Full Text] [Related]
22. Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
Bastian AJ; Kelly VE; Perlmutter JS; Mink JW
Mov Disord; 2003 Sep; 18(9):1008-17. PubMed ID: 14502668
[TBL] [Abstract][Full Text] [Related]
23. [Levodopa and cognitive disorders in Parkinson's disease].
Leiva-Santana C; Alvarez-Saúco M
Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
26. Second-generation dopamine agonists and recollection impairments in Parkinson's disease.
Shepherd TA; Edelstyn NM; Mayes AR; Ellis SJ
J Neuropsychol; 2013 Sep; 7(2):284-305. PubMed ID: 23815454
[TBL] [Abstract][Full Text] [Related]
27. Slowing of high-speed memory scanning in Parkinson's disease is related to the severity of parkinsonian motor symptoms.
Ransmayr G; Bitschnau W; Schmidhuber-Eiler B; Berger W; Karamat E; Poewe W; Kemmler GW
J Neural Transm Park Dis Dement Sect; 1990; 2(4):265-75. PubMed ID: 1964055
[TBL] [Abstract][Full Text] [Related]
28. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?
Pillon B; Dubois B; Cusimano G; Bonnet AM; Lhermitte F; Agid Y
J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):201-6. PubMed ID: 2703838
[TBL] [Abstract][Full Text] [Related]
29. Semantic activation in patients with Parkinson's disease.
Hines TM; Volpe BT
Exp Aging Res; 1985; 11(2):105-7. PubMed ID: 4092717
[TBL] [Abstract][Full Text] [Related]
30. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Vaamonde J; Luquin MR; Obeso JA
Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
[TBL] [Abstract][Full Text] [Related]
31. Cognitive effects of methylphenidate and levodopa in healthy volunteers.
Linssen AM; Sambeth A; Vuurman EF; Riedel WJ
Eur Neuropsychopharmacol; 2014 Feb; 24(2):200-6. PubMed ID: 24119823
[TBL] [Abstract][Full Text] [Related]
32. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.
Rafal RD; Posner MI; Walker JA; Friedrich FJ
Brain; 1984 Dec; 107 ( Pt 4)():1083-94. PubMed ID: 6509309
[TBL] [Abstract][Full Text] [Related]
33. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels.
Kulisevsky J; Avila A; Barbanoj M; Antonijoan R; Berthier ML; Gironell A
Brain; 1996 Dec; 119 ( Pt 6)():2121-32. PubMed ID: 9010015
[TBL] [Abstract][Full Text] [Related]
34. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
Cooper JA; Sagar HJ; Doherty SM; Jordan N; Tidswell P; Sullivan EV
Brain; 1992 Dec; 115 ( Pt 6)():1701-25. PubMed ID: 1486457
[TBL] [Abstract][Full Text] [Related]
35. Short-term memory and temporal ordering in early Parkinson's disease: effects of disease chronicity and medication.
Cooper JA; Sagar HJ; Sullivan EV
Neuropsychologia; 1993 Sep; 31(9):933-49. PubMed ID: 8232850
[TBL] [Abstract][Full Text] [Related]
36. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa.
Gotham AM; Brown RG; Marsden CD
Brain; 1988 Apr; 111 ( Pt 2)():299-321. PubMed ID: 3378138
[TBL] [Abstract][Full Text] [Related]
37. [Psychological changes in patients with Parkinson's disease during treatment with L-Dopa. Interpretation and comprehension of the observed phenomena].
Fau R; Perret J; Israël L; Ohlmann T
Ann Med Psychol (Paris); 1975 May; 1(5):670-83. PubMed ID: 1233896
[No Abstract] [Full Text] [Related]
38. Dopaminergic modulation of prospective memory in Parkinson's disease.
Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
Behav Neurol; 2008; 19(1-2):45-8. PubMed ID: 18413916
[TBL] [Abstract][Full Text] [Related]
39. Fractionating the Neurocognitive Mechanisms Underlying Working Memory: Independent Effects of Dopamine and Parkinson's Disease.
Fallon SJ; Mattiesing RM; Muhammed K; Manohar S; Husain M
Cereb Cortex; 2017 Dec; 27(12):5727-5738. PubMed ID: 29040416
[TBL] [Abstract][Full Text] [Related]
40. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction.
Lange KW; Robbins TW; Marsden CD; James M; Owen AM; Paul GM
Psychopharmacology (Berl); 1992; 107(2-3):394-404. PubMed ID: 1615139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
